source
- PTC Therapeutics acquires Sangamo’s Fabry gene therapy program for $111 million upfrontPTC Therapeutics announced it has purchased the Fabry disease gene-therapy program (ST-920) from Sangamo Therapeutics. The deal provides $111 million in upfront cash and includes up to $100 millio…
- Versa Vascular appoints former Medtronic heart franchise leader Bill Shields as CEOBill Shields, who spent 15 years leading Medtronic’s structural heart franchise, is leaving the medtech giant to become chief executive of Versa Vascular, a startup developing tricuspid valve repai…